

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

April 12, 2021

Iraj Ali, Ph.D. Chief Executive Officer Achilles Therapeutics plc 245 Hammersmith Road London W6 8PW United Kingdom

> Re: Achilles Therapeutics plc Form F-1, as amended Exhibit No. 10.7 Filed March 29, 2021 File No. 333-253735

Dear Dr. Ali:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance